Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 14/20 | 0.57 |
| ▸ | CCR9 | P51686 | 1/20 | 0.44 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.43 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.42 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4091277 | 0.91 | CCR2 (0.47) | CCR2CCR9ABCB11GPR35MAPT | |
| SCHEMBL4097557 | 0.89 | CCR2 (0.47) | CCR2CCR9ABCB11GPR35MAPT | |
| SCHEMBL4086732 | 0.88 | MAPT (0.55) | CCR2MAPT | |
| SCHEMBL4086414 | 0.83 | CCR2 (0.48) | CCR2CCR9ABCB11 | |
| SCHEMBL4091073 | 0.80 | CCR2 (0.38) | CCR2CCR9ABCB11GPR35MAPT | |
| SCHEMBL4097150 | 0.80 | PTGES (0.47) | CCR2ERCC5MAPT | |
| SCHEMBL4086016 | 0.79 | CCR2 (0.49) | CCR2CCR9MAPT | |
| SCHEMBL4102959 | 0.76 | MAPT (0.58) | MAPT | |
| SCHEMBL4092463 | 0.75 | CCR2 (0.55) | CCR2CCR9ABCB11MAPT | |
| SCHEMBL3957310 | 0.74 | CCR2 (1.00) | CCR2CCR9GPR35 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069384-A1 | THIENOPYRROLES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069384-A1 | THIENOPYRROLES USEFUL IN THE TREATMENT OF INFLAMMATION | NPY5R, TH, PTGES | CCR2 1118/4885CCR9 2391/4885ABCB11 4077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.